Illustration: Allie Carl/Axios
Brain disorder biotech MapLight Therapeutics raised $258 million in its IPO and a private placement with Goldman Sachs.
Why it matters: Maplight's debut comes on the heels of LB Pharma's September IPO, as the schizophrenia treatment market heats up.
